U.S. Markets close in 2 hrs 44 mins

Novavax reports progress on RSV vaccine

Novavax reported that RSV vaccine candidate induced anti-RSV antibodies capable of neutralizing RSV in vitro and significantly reduced infectious RSV in a cotton rat challenge model. Further, in both clinical and preclinical studies, the company reported that palivizumab-competing antibodies were generated at titers significantly above that found to be protective in both humans and cottons rats.